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Biotinylated photoactive Pt(IV) anticancer
complexes†
Huayun Shi, Cinzia Imberti, Huaiyi Huang, Ian Hands-Portman and
Peter J. Sadler *
Novel biotinylated diazido-Pt(IV) complexes exhibit high visible light
photocytotoxicity while being stable in the dark. Photocytotoxicity
and cellular accumulation of all-trans-[Pt(py)2(N3)2(biotin)(OH)] (2a)
were enhanced significantly when bound to avidin; irradiation
induced dramatic cellular morphological changes in human ovarian
cancer cells treated with 2a.
Tumour-targeting drugs can improve selective drug delivery to
cancer cells and reduce undesirable side effects.1–4 Biotin
(vitamin H or B7) plays an important role as cellular growth
promoter and co-enzyme for carboxylase enzymes.5 Exogenous
biotin is taken up via a high-affinity biotin transporter and
a sodium-dependent multivitamin transporter (SMVT).6,7
Notably, cancer cells overexpress SMVT, thus making biotin a
tumour-targeting vector.8–10 Biotin possesses a high affinity
specific for tetrameric egg white avidin through noncovalent
bonding with Kd values of 10
13 to 1015 M.11 The avidin–biotin
complex induces a relatively low immune response in vivo and
has been widely used in cancer-targeted therapy.5,12–15 Avidin
displays strong adherence to cells in vitro, and can be administered
as a nano-carrier for delivery of biotinylated drugs.16 Biotinylation
of drugs is therefore a feasible strategy to improve their cancer-cell
accumulation and selectivity,17,18 and has also been applied in the
design of photoactive drugs.19–22
Photoactive Pt agents provide spatial control of cytotoxicity
with novel mechanisms of action and lack of cross-resistance
with cisplatin.23,24 Diazido Pt(IV) complexes are potent photo-
active prodrugs with high dark stability due to their kinetic
inertness,25–27 and photocytotoxicity exerted by the combined
effects of Pt(II) products, azidyl radicals and reactive oxygen
species (ROS) formed on photoactivation.28–30 Trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (1) kills cancer cells upon irradiation with
high photocytotoxicity (dark versus light) indices.27 Axial OH
ligands enhance aqueous solubility of Pt(IV) complexes and
stabilise the PtIV oxidation state.31 Derivatisation of the relea-
sable axial ligand can improve the pharmacological properties
without altering the mechanism of action.32–34
Herein, we have prepared two novel biotinylated diazido Pt(IV)
complexes trans,trans,trans-[Pt(py)2(N3)2(biotin)(OH)] (2a) and
trans,trans,trans-[Pt(py)2(N3)2(biotin)(DCA)] (2b, Scheme 1). The
pyruvate dehydrogenase kinase (PDK) inhibitor dichloroacetate
(DCA) can be delivered to cancer cells effectively as an axial ligand
in Pt(IV) prodrugs.35–37 Dark stability, photodecomposition, photo-
reactions with 50-GMP and DNA, and interaction with avidin were
investigated for 2a and 2b, and their photocytotoxicity and cellular
accumulation compared to those of avidin-complex adducts.
Cellular morphological changes upon treatment of cancer cells
with 2a were examined by confocal microscopy.
The synthetic routes for photoactive Pt(IV) complexes 2a and 2b
are summarised in Scheme 1.Mono-substituted 2awas obtained by
combining 1 with biotin using TBTU/DIPEA as coupling agents,
while the bi-substituted 2b was synthesised by stirring 2a with DCA
anhydride. Both complexes gave satisfactory elemental analyses
and were also characterised by ESI-HRMS, NMR and UV-vis
spectroscopy, and for purity by HPLC (Fig. S1, ESI†).
Scheme 1 Synthetic routes for biotinylated complexes 2a and 2b.
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The 1H and 13C NMR data are consistent with the proposed
structures of the complexes. The Pt-coordinated pyridine has
characteristic 1H NMR doublets with 195Pt satellites at ca. 8.8 ppm,
and the triplets at ca. 8. 3 and 7.9 ppm, with 13C NMR resonances
at ca. 150, 143 and 127 ppm (Fig. S2–S5, ESI†). Two typical singlets
at 6.38 and 6.35 ppm assignable to NHC(O)NH of biotin were
detected for both complexes. The electronic absorption spectra of
2a and 2b in aqueous solution were similar, although 2b exhibited
a slight red shift of the LMCT (N3- Pt) transition and stronger
absorption at wavelengths o270 nm due to the presence of the
DCA ligand.
Complexes 2a and 2b exhibited excellent dark stability in
RPMI-1640/DMSO (95%/5%, v/v) monitored by UV-vis spectro-
scopy (Fig. 1a and Fig. S6a, ESI†). When irradiated with blue
light (420 nm), the LMCT bands of both complexes at
ca. 300 nm decreased in intensity, indicating release of the
azide ligands (Fig. 1b and Fig. S6b, ESI†).27 Notably, 2b exhibited
a larger decrease at the absorption maximum, probably due to
release of the DCA ligand. Released azidyl radicals and singlet
oxygen were trapped by DMPO and TEMP, respectively, for 2a
upon irradiation (463 nm; Fig. 1c and d).
The photoreactions of 2a/2b with 50-GMP were analysed by
LC-MS. Pt(IV) complexes (30 mM) were incubated with 50-GMP
(2 mol equiv.) at 310 K in the dark for 1 h, then irradiated by
blue light (420 nm) for 1 h (Fig. S7, ESI†). For both complexes,
[PtII(CH3CN)(py)2(GMP-H)]
+ (G1, 756.48 m/z) was detected as
the major Pt-GMP product, together with two minor adducts
[PtII(HCOO)(py)2(GMP)]
+ (G2, 762.18m/z) and [PtII(N3)(py)2(GMP)]
+
(G3, 758.23 m/z). These results were similar to those obtained
for 1, suggesting a negligible effect of axial substituents on the
photoreaction with guanine.38
DNA melting experiments monitored by UV-vis were carried
out in phosphate buffer (1 mM, pH = 7.9) to investigate DNA
binding with a drug/base pair ratio of 0.2 (Table S1, ESI†).
Similar to parent complex 1, 2a and 2b interact with ct-DNA
only weakly (DTm o 2 K) in the dark, while upon irradiation
with blue light (420 nm) an apparent interaction was observed
(DTm ca. 5 K). The increase in the DNA melting temperature
suggests that 2a and 2b might form inter-strand cross-links
after irradiation, similar to 1.
The binding affinity of avidin towards 2a and 2b in PBS was
assessed by a displacement titration using HABA (2-(4-hydroxy-
phenylazo)benzoic acid) and monitored by UV-vis spectroscopy
(Fig. 2). The avidin–HABA adduct displays an absorption band
at ca. 496 nm, which decreases when HABA is replaced by
biotin.39 On mixing, a gradual decrease of the absorbance at
496 nm was observed upon addition of either complex to a
solution containing HABA (160 mM) and avidin (8 mM), indicat-
ing their stronger binding to avidin compared with HABA
(dissociation constant Kd = 10
6 M).39 A sharp end point and
same absorbance changes (DA = 1.01) with biotin were observed
for 2a and 2b, indicating their similar affinity towards avidin as
unmodified biotin. These results suggested the possibility
of using avidin as a nanocarrier for delivery of biotinylated
complexes to cancer cells.
The IC50 values of 2a and 2b in human A2780 ovarian, A549
lung and PC3 prostate cancer cell lines were determined by the
sulforhodamine B (SRB) colorimetric assay (Table 1), using
parent complex 1 and CDDP (cisplatin) as references. Both
complexes were relatively non-toxic towards all cancer cells and
healthy MRC-5 lung fibroblasts in the dark with IC50 values
450/100 mM, but exhibited promising photocytotoxicity with
high photocytotoxicity indices (PI). In all the cancer cell lines
studied, di-substituted 2b (1.3–5.9 mM) is at least twice as
phototoxic as the mono-substituted 2a (11.7–21.1 mM), and
5 more toxic than 1 (7.1–55.6 mM). Under the same condi-
tions, cisplatin exhibited very low cytotoxicity in all cell lines
(IC50 4 100 mM) due to the short incubation time (2 h).
In A2780 ovarian cancer cells, 2a (IC50 = 11.7 mM) was slightly
less active than 1 (IC50 = 7.1 mM), while 2b was more potent
(IC50 = 1.3 mM), potentially attributable to the synergistic anti-
cancer activity of the released DCA ligand. In order to investigate
the effect of avidin on activity, 2a was mixed with avidin
(2a : avidin = 4 : 1) prior to addition to A2780 cells following the
same protocol used for 2a alone. Notably, the avidin–2a complex
exhibited good dark stability, being potently photocytotoxic in
A2780 cells with an IC50 value of 4.4 mM, 2.7 lower than that of
2a, and 1.6more toxic than 1. In contrast, the photocytotoxicity
of 2b was not enhanced in the presence of avidin.
Fig. 1 (a) UV-vis spectral changes for 2a (50 mM) in RPMI-1640 in the dark
for 2 h, and (b) in H2O upon 1 h irradiation with blue light (420 nm); (c) EPR
spectra for 2a (2.5 mM) with DMPO in H2O after irradiation (463 nm), and
(d) with TEMP in CH3CN in the dark ( ) and after irradiation (463 nm, —).
Fig. 2 (a) UV-vis spectral changes for avidin–HABA in PBS solution upon
addition of complex 2a in DMSO, (b) absorbance change at 496 nm in
HABA displacement titrations of biotinylated complexes 2a.
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Since biotin is expected to exhibit a preference towards cancer
cells due to overexpressed receptors,5 ICP-MS was used to quantify
and compare the cellular uptake of biotinylated complexes 2a and
2b as well as the unsubstituted 1. A2780 ovarian cancer cells were
treated with 10 mMprodrugs in the dark for 1 h, then the Pt content
of cells was analysed by ICP-MS (Table 2). The mono-substituted 2a
exhibited lower Pt accumulation (0.4 ng per 106 cells) than 1
(0.64 ng per 106 cells) after 1 h incubation, while accumulation of
di-substituted 2b (21.1 ng per 106 cells) was 33 higher than that
of 1 and 53 higher than 2a. These results showed that
conjugation with biotin alone did not increase the accumulation
of diazido Pt(IV) complexes in A2780 cells, while the substitution
of the second axial ligand with DCA resulted in significant
increase in Pt cellular accumulation, perhaps due to higher
lipophilicity of 2b, consistent with its longer HPLC retention
time (12.3 min for 2a, 19.7 min for 2b, Fig. S1, ESI†). Notably, the
amount of Pt taken up by A2780 cells incubated with 1, 2a and 2b
was inversely proportional to their IC50 values. These results
suggested that cellular accumulation of Pt(IV) prodrugs plays
an important role in their antiproliferative activity. Since the
avidin–2a complex exhibited improved photocytotoxicity, the
effect of avidin on the uptake of 2a was also investigated.
The accumulation of Pt after exposure of A2780 cells to themixture
of 10 mM 2a and avidin (4 : 1) was 10 higher than 2a alone, which
correlates with the higher photocytotoxicity of 2a–avidin complex.
However, Pt accumulation for 1 and 2b was not affected by
avidin, since 1 does not contain biotin and 2b is mainly taken
up by passive diffusion due to its high lipophilicity.
A2780 ovarian cancer cells were treated with 2a (1 or 2
photo IC50 concentration) in the presence and absence of light
and live-imaged using confocal microscopy and flow cytometry
to investigate changes in cell morphology (Fig. 3 and Fig. S8,
S10, ESI†). The cell permeant dye SYTOt 17 was used to stain
the nuclei. Without irradiation, 2a exhibited low cytotoxicity
(IC50 4 100 mM) and, accordingly, no changes in cellular mor-
phology were observed when cells were treated with 2a for 2 h in
the dark. In these conditions, the cells appeared healthy with well-
defined plasma membranes and intact nuclei. In contrast, A2780
cells treated with 2a exhibited dramatic morphological changes
after 1 h irradiation with blue light (465 nm). The cells rounded
up and the nuclei were fragmented into pieces. Damaged mem-
branes and copious cell debris were observed when cells were
treated with 2a at 2  IC50 concentration (Fig. 3 and Fig. S10,
ESI†). DNA is usually regarded as the major target of platinum
anticancer drugs, so the ability of 2a to fragment cell nuclei
exclusively upon irradiation, indicated its potential as a photo-
active prodrug with a novel mechanism of action. Complex 2a at
higher concentration induced more morphological changes upon
irradiation, while irradiation alone did not result in significant
effects on cell morphology (Fig. S9 and S10, ESI†).
Cellular ROS generation for 2a, 2b and 1 was monitored in
A549 lung cancer cells by DCFH-DA, which exhibits switch-on
fluorescence in the presence of ROS. Cells treated with com-
plexes (10 mM) in the dark showed no apparent change, but 2b
induced an increased DCF fluorescence upon irradiation, indi-
cating its ability to generate ROS (Table S2, ESI†).
In summary, two novel biotinylated Pt(IV) complexes trans,-
trans,trans-[Pt(py)2(N3)2(biotin)(OH)] (2a) and trans,trans,trans-
[Pt(py)2(N3)2(biotin)(DCA)] (2b) have been synthesised and
characterised. They exhibited good dark stability and promising
Table 1 IC50 values and photocytotoxicity indices (PI) for 2a and 2b
obtained after 1 h incubation, 1 h irradiation (465 nm) and 24 h recovery,
in comparison with the parent complex 1 and CDDP (cisplatin)34
Comp.
Cell line/IC50 (mM)
a
A2780 A549 PC3 MRC5
2a Dark 4100 4100 4100 4100
Irrad 11.7  0.3 13.3  0.7 21.1  0.4
PI 48.5 47.5 44.7
2a–avi (4 : 1) Dark 4100
Irrad 4.4  0.3
PI 422.7
2b Dark 450 4100 4100 4100
Irrad 1.3  0.2 5.9  0.6 3.0  0.1
PI 438.5 416.9 433.3
2b–avi (4 : 1) Dark 450
Irrad 2.45  0.01
PI 420.4
1 Dark 4100 4100 4100 4100
Irrad 7.1  0.4 51.9  2.5 55.6  0.9
PI 414.1 41.9 41.8
CDDP Dark 4100 4100 4100 4100
Irrad 4100 4100 4100
a Data are from three independent experiments.
Table 2 Cellular Pt accumulation in A2780 ovarian cancer cells after
exposure to complexes 2a, 2b and 1, and the effect of avidin (10 mM Pt
complex, 1 h incubation in the dark)
Pt accumulation (ng per 106 cells)a
Complex Complex with avidin
2a 0.40  0.15* 2a–avi (4 : 1) 4.1  0.7*
2b 21.1  2.0*** 2b–avi (4 : 1) 20.0  1.5***
1 0.64  0.07*** 1–avi (4 : 1) 0.56  0.09**
a All experiments were conducted in triplicate. Comparison with
untreated controls was performed by a two-tail t-test with unequal
variances. *p o 0.05, **p o 0.01, ***p o 0.005.
Fig. 3 Fluorescence images of A2780 ovarian cancer cells treated with 2a
(2  photo IC50 concentration) in the dark and after irradiation with
blue light (l = 465 nm). Cells were stained by SYTOt 17 (2.5 mM, lex/lem =
633/638–759 nm) for 30 min. Scale bar = 20 mm (10 mm in magnification).
Fragmented nuclei and damaged membranes of A2780 cells treated with
2a were observed upon irradiation, while in the dark, cells were intact and
well-defined.
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photoactivity, releasing azidyl radicals and generating singlet
oxygen. Photoreactions with 50-GMP resulted in the formation of
[PtII(CH3CN)(py)2(GMP-H)]
+ as a major product. An increase in
ct-DNA melting temperature suggested formation of inter-strand
crosslinks. Promising photocytotoxicity of 2a and 2b towards
human A2780 ovarian, A549 lung and PC3 prostate cancer cells
was observed upon irradiation with low-dose blue light (465 nm,
4.8 mW cm2, 1 h), with high photocytotoxicity indices. The
di-substituted 2b exhibited much higher photocytotoxicity and
cellular Pt accumulation, compared with mono-substituted 2a
and unsubstituted 1. The strong interaction of 2a and 2b with
avidin was confirmed by HABA displacement from avidin–HABA.
When A2780 ovarian cancer cells were incubated with 1 :4 avidin :2a,
both photocytotoxicity and cellular accumulation increased
significantly. Dramatic morphological changes in A2780 cells
were observed after irradiation with 2a, consistent with its
promising photocytotoxicity.
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